There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arrowhead Research (NASDAQ:ARWR) and Jazz Pharmaceuticals (NASDAQ:JAZZ) with bullish sentiments.
Arrowhead Research (ARWR)
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Arrowhead Research yesterday and set a price target of $18. The company’s shares closed yesterday at $15.10, close to its 52-week high of $17.50.
Piros wrote:
“: We reiterate our Overweight rating and are raising our 12-month PT to $18/share from $13/share following 3Q18 financial and corporate updates from Arrowhead Pharmaceuticals. The company hosted a call and highlighted upcoming data presentations at AASLD (pending abstract acceptances) for two lead indications (ARO-HBV and ARO-AAT) and provided updates to additional TRiM candidates that are approaching or have already entered the clinic.”
According to TipRanks.com, Piros ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.8% and a 38.5% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Arrowhead Research has an analyst consensus of Strong Buy, with a price target consensus of $17.50, a 15.9% upside from current levels. In a report issued on July 23, William Blair also maintained a Buy rating on the stock with a $30 price target.
.
See today’s analyst top recommended stocks >>
Jazz Pharmaceuticals (JAZZ)
Cantor Fitzgerald analyst William Tanner reiterated a Buy rating on Jazz Pharmaceuticals yesterday and set a price target of $203. The company’s shares closed yesterday at $179.90, close to its 52-week high of $184.
Tanner commented:
“: We reiterate our Overweight rating and $203 PT on JAZZ stock. Efforts over the last few years to expand the sleep franchise and to establish an orphan oncology business have positioned the company well, in our view, to create attractive and durable future growth opportunities. Pending release of Phase 3 data, we believe it reasonable to view JZP-258 as a viable product to retain share of the sodium oxybate market. Even if the competition proves to be staunch, the aggregate opportunities for other programs/franchises could be significantly larger than what JAZZ might cede, in our opinion.”
According to TipRanks.com, Tanner is a 2-star analyst with an average return of 1.3% and a 43.7% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $200.20 average price target, an 11.3% upside from current levels. In a report issued on July 24, Piper Jaffray also reiterated a Buy rating on the stock with a $210 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
